Format
Sort by
Items per page

Send to

Choose Destination

Best matches for tazarotene/PD:

Pharmacokinetics of tazarotene and acitretin in psoriasis. Heath MS et al. Expert Opin Drug Metab Toxicol. (2018)

Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy Tanghetti E et al. J Drugs Dermatol. (2018)

Palmoplantar psoriasis. Engin B et al. Clin Dermatol. (2017)

Search results

Items: 1 to 20 of 355

1.

Risankizumab (Skyrizi) for psoriasis.

[No authors listed]

Med Lett Drugs Ther. 2019 Jun 3;61(1573):81-83. No abstract available.

PMID:
31170118
2.

Quantification and In Silico Toxicity Assessment of Tazarotene and its Impurities for a Quality and Safe Drug Product Development.

Nagulakonda NNM, Ananthula RS, Krishnamurthy T, Rao MRP, Rao GN.

J Chromatogr Sci. 2019 Aug 1;57(7):625-635. doi: 10.1093/chromsci/bmz037.

PMID:
31037297
3.
4.

Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis

Blauvelt A, Green LJ, Lebwohl MG, Yamauchi PS, Lin T, Martin G, Pillai R.

J Drugs Dermatol. 2019 Mar 1;18(3):297-299.

PMID:
30909352
5.

Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis

Kircik LH, Papp KA, Stein Gold L, Harris S, Pharm TL, Pillai R.

J Drugs Dermatol. 2019 Mar 1;18(3):279-284..

PMID:
30909333
6.
7.

Tildrakizumab (Ilumya) - another IL-23 antagonist for psoriasis.

[No authors listed]

Med Lett Drugs Ther. 2019 Jan 14;60(1563):4-6. No abstract available.

PMID:
30681661
8.

Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis

Stein Gold L, Bagel J, Lebwohl M, Lin T, Martin G, Pillai R.

J Drugs Dermatol. 2018 Dec 1;17(12):1290-1296.

PMID:
30586261
9.

Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy

Tanghetti E, Lebwohl M, Stein Gold L.

J Drugs Dermatol. 2018 Dec 1;17(12):1280-1287. Review.

PMID:
30586259
10.

Regulation of Chemerin and CMKLR1 Expression by Nutritional Status, Postnatal Development, and Gender.

Sanchez-Rebordelo E, Cunarro J, Perez-Sieira S, Seoane LM, DiƩguez C, Nogueiras R, Tovar S.

Int J Mol Sci. 2018 Sep 25;19(10). pii: E2905. doi: 10.3390/ijms19102905.

11.

Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis.

Lebwohl MG, Sugarman JL, Gold LS, Pariser DM, Lin T, Pillai R, Martin G, Harris S, Israel R.

J Am Acad Dermatol. 2019 Jan;80(1):282-285. doi: 10.1016/j.jaad.2018.09.002. Epub 2018 Sep 15. No abstract available.

12.

Pharmacokinetics of tazarotene and acitretin in psoriasis.

Heath MS, Sahni DR, Curry ZA, Feldman SR.

Expert Opin Drug Metab Toxicol. 2018 Sep;14(9):919-927. doi: 10.1080/17425255.2018.1515198. Epub 2018 Sep 3. Review.

PMID:
30134735
13.

Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.

Stein Gold L, Kircik LH, Pariser D, Sugarman JL, Lin T, Kang R, Pillai R.

J Drugs Dermatol. 2018 Aug 1;17(8):863-868.

PMID:
30124725
14.

Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.

Sugarman JL, Weiss J, Tanghetti EA, Bagel J, Yamauchi PS, Stein Gold L, Lin T, Martin G, Pillai R, Israel R.

J Drugs Dermatol. 2018 Aug 1;17(8):855-861.

PMID:
30124724
15.

Fractional carbon dioxide laser assisted delivery of topical tazarotene versus topical tioconazole in the treatment of onychomycosis.

Abd El-Aal EB, Abdo HM, Ibrahim SM, Eldestawy MT.

J Dermatolog Treat. 2019 May;30(3):277-282. doi: 10.1080/09546634.2018.1509046. Epub 2018 Sep 28.

PMID:
30081698
16.

Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.

Pariser DM, Green LJ, Stein Gold L, Sugarman JL, Lin T, Pillai R.

J Drugs Dermatol. 2018 Jul 1;17(7):723-726.

PMID:
30005093
17.

Tazarotene gel with narrow-band UVB phototherapy: a synergistic combination in psoriasis.

Dayal S, Kaura R, Sahu P, Jain VK.

An Bras Dermatol. 2018 Jun;93(3):385-390. doi: 10.1590/abd1806-4841.20186723.

18.

Tazarotene-Induced Gene 1 Interacts with DNAJC8 and Regulates Glycolysis in Cervical Cancer Cells.

Wang CH, Shyu RY, Wu CC, Chen ML, Lee MC, Lin YY, Wang LK, Jiang SY, Tsai FM.

Mol Cells. 2018 Jun;41(6):562-574. doi: 10.14348/molcells.2018.2347. Epub 2018 Jun 14.

19.

Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision.

Donigan JM, Hyde MA, Goldgar DE, Hadley ML, Bowling M, Bowen GM.

JAMA Dermatol. 2018 Aug 1;154(8):885-889. doi: 10.1001/jamadermatol.2018.0530.

20.

Erythematous Papular Lesions on the Neck: A Quiz.

Mouchard A, Tallegas M, Machet MC, Machet L, Cornillier H.

Acta Derm Venereol. 2018 Aug 29;98(8):822-823. doi: 10.2340/00015555-2971. No abstract available.

Supplemental Content

Loading ...
Support Center